Key result
Protein kinase inhibitors can trigger multiple pulmonary hypertension subtypes, spanning Groups 1, 2, and 3.
Why the study?
Protein kinase inhibitors are implicated in pulmonary vascular toxicities, including risk factors for at least three WHO pulmonary hypertension groups via direct drug-induced pulmonary arterial hypertension, cardiomyopathies, and interstitial lung disease.
Do protein kinase inhibitors cause pulmonary hypertension in patients with cancer?
Do protein kinase inhibitors cause pulmonary hypertension in patients with cancer?
This review provides a framework for identifying and managing the different types of pulmonary hypertension that can arise as toxicities from protein kinase inhibitor therapy.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor cancer patients on protein kinase inhibitors for pulmonary hypertension subtypes; leaves open prospective validation of incidence and management.
Protein kinase inhibitors (PKIs) have been implicated in pulmonary vascular toxicities including risk factors for at least three of the five World Health Organization groups of pulmonary hypertension (PH). These toxicities include direct drug-induced pulmonary arterial hypertension, an increase in cardiomyopathies, and an increase in interstitial lung disease. On- and off-target toxicities are common within multitargeted PKIs leading to cardiopulmonary toxicities. This review highlights the incidence, possible mechanisms, and management strategies for each group of possible PKI-induced PH. Future identification and clarification of protein kinase pathways for both mechanisms of toxicity and pathophysiology for PH could lead to improvements in patient care in oncology and pulmonary vascular diseases.
No takes yet. Share an insight, caveat, or question.
Jacobs et al. (2022) conducted a review in Pulmonary hypertension associated with protein kinase inhibitors. Protein kinase inhibitors was evaluated. Protein kinase inhibitors can induce multiple forms of pulmonary hypertension, including Group 1 PAH, Group 2 PH from left heart disease, and Group 3 PH from interstitial lung disease.
Synapse has enriched 10 related papers. Consider them for comparative context: